John W. Davis, MD, FACS, presented “Grade Group 1 at Biopsy – Do We Need to Know More?” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Davis, John W. “Grade Group 1 at Biopsy – Do We Need to Know More?” February 9, 2025. Accessed May 2025. https://grandroundsinurology.com/grade-group-1-at-biopsy-do-we-need-to-know-more/
Grade Group 1 at Biopsy – Do We Need to Know More? – Summary
John W. Davis, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, Texas, explores the evolving landscape of prostate cancer diagnostics and management. In this 15-minute presentation, Dr. Davis focuses on grade group one disease.
MRI utilization before biopsy remains limited in community settings, with rates improving but still below optimal levels. Emphasizing insights from studies such as the PROTECT trial, outcomes reveal that active surveillance shows comparable long-term survival to immediate treatment in low-risk prostate cancer.
Dr. Davis underscores the importance of confirmatory biopsies, MRI guidance, and tailored surveillance protocols to improve diagnostic precision. Workflow enhancements, including clear algorithms and second-opinion pathology, streamline decision-making, particularly in referral centers. While genomic markers may have selective value, the overarching message encourages maximizing diagnostic tools while avoiding overtreatment of grade group one disease.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
John W. Davis, MD, is a Professor of Urology and Director of the Urosurgical Prostate Program at the University of Texas MD Anderson Cancer Center in Houston. He received his BS in Biology at Davidson College in North Carolina in 1990. He then went on to earn his medical degree at the University of Virginia in 1994 and completed his residency training at Eastern Virginia Graduate School of Medicine in Norfolk. Dr. Davis had fellowship training in prostate cancer research in the Department of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, and received an American Foundation of Urologic Disease Scholar award for proteomic applications in prostate cancer biomarkers. He completed a Clinical Fellowship in Urologic Oncology at the MD Anderson Cancer Center, and a Fellowship in Laparoscopic Urology at Charité Hospital in Berlin, Germany, under the mentorship of Ingolf Tuerk.
Dr. Davis’ clinical interests include patients with urologic cancers, laparoscopic/robotic surgery, and general urology. His academic interests include quality of life after prostate cancer treatment, outcomes for robotic radical prostatectomy, high-risk prostate cancer trials, active surveillance for prostate cancer, and development of robotic surgical techniques for invasive bladder cancer. He has participated as an investigator in several Southwest Oncology Group and industry-sponsored clinical trials.
